The BCL2 Knockout CAL-27 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population, with targeted disruption of the BCL2 gene in the CAL-27 human tongue squamous cell carcinoma line. This knockout model provides a valuable loss-of-function system for elucidating the role of the anti-apoptotic protein BCL2 in oral cancer biology. The product is supplied as a polyclonal mixture, derived by CRISPR/Cas9-mediated gene disruption, which avoids clonal selection artifacts and better reflects heterogeneous tumor cell responses.
CAL-27 is an adherent epithelial cell line originally isolated from a squamous cell carcinoma of the tongue. As a widely employed model for head and neck squamous cell carcinoma (HNSCC), CAL-27 cells exhibit characteristic epithelial morphology and tumorigenic properties, making them a standard platform for studying apoptosis regulation, drug sensitivity, and oncogenic signaling networks in the oral cavity context.
BCL2 encodes a key anti-apoptotic protein that functions primarily at the mitochondrial outer membrane, where it binds and neutralizes pro-apoptotic BH3-only proteins such as BAX, BAK, BAD, BIM, PUMA, and NOXA. By preventing BAX/BAK pore formation, BCL2 blocks cytochrome c release, APAF1 apoptosome assembly, and subsequent activation of caspase-9 and caspase-3, thereby inhibiting the intrinsic apoptotic pathway. Upstream signals including MYC, TP53, NF-??B, PI3K/AKT, and JNK regulate BCL2 expression and activity, integrating survival cues from cytokines like IL-3, IL-6, and EGF to fine-tune mitochondrial apoptosis.
In the context of CAL-27 cells, BCL2 overexpression is frequently associated with apoptotic resistance and poorer prognosis in HNSCC. Disruption of BCL2 in this polyclonal knockout population enables researchers to dissect survival mechanisms and interrogate how BCL2-dependent pathways contribute to oral cancer progression. The model also facilitates comparative studies with wild-type CAL-27 cells to define the functional impact of BCL2 loss on mitochondrial integrity and chemosensitivity.
These polyclonal knockout cells are applicable to a range of experimental workflows, including Annexin V/PI flow cytometry apoptosis assays, MTT cell viability measurements, and JC-1-based mitochondrial membrane potential quantification. They support Western blotting analysis of BCL2, BAX, cleaved caspase-3, and co-immunoprecipitation of BCL2-BAX complexes. Research applications encompass BCL2 inhibitor drug screening, mechanistic studies of apoptotic resistance, and evaluation of combination therapies targeting the intrinsic apoptosis pathway. For further information, please contact Ascent Research.
